Imunon CEO Corinne Le Goff resigns; Executive Chairman Tardugno assumes interim leadership

Imunon, Inc.

Dr. Corinne Le Goff resigned as President, CEO, and Board member, effective March 15, 2024, to pursue another opportunity.
Resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Executive Chairman Michael H. Tardugno (former CEO) will lead day-to-day operations until a successor is named.
Active CEO search is underway; development strategy and key program milestones remain unchanged.
Milestones: Phase 1 trial of IMNN-101 (COVID-19 booster) prep ongoing; OVATION 2 topline data for IMNN-001 expected summer 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Corinne Le Goff

President and Chief Executive Officer

IMNN · Imunon, Inc.

Effective: 2024-03-15
Filed: March 12, 2024, 7:59 PM ET

On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the “Board”) of Imunon, Inc. (the “Company”) of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Corinne Le Goff resigned as President and Chief Executive Officer at Imunon, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the “Board”) of Imunon, Inc. (the “Company”) of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.